- Home
- Publications
- Publication Search
- Publication Details
Title
Molnupiravir in COVID-19: A systematic review of literature
Authors
Keywords
Molnupiravir, EIDD-2801, MK-4482, COVID-19, SARS-CoV-2
Journal
Diabetes & Metabolic Syndrome-Clinical Research & Reviews
Volume 15, Issue 6, Pages 102329
Publisher
Elsevier BV
Online
2021-10-30
DOI
10.1016/j.dsx.2021.102329
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
- (2021) Wendy P. Painter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
- (2021) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- β-D-N 4-hydroxycytidine (NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
- (2021) Shuntai Zhou et al. JOURNAL OF INFECTIOUS DISEASES
- Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
- (2021) Kyle Rosenke et al. Nature Communications
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
- (2021) Saye H Khoo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
- (2021) Florian Kabinger et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports
- (2021) Elisabeth Mahase BMJ-British Medical Journal
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
- (2020) Robert M. Cox et al. Nature Microbiology
- Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
- (2019) Maria L. Agostini et al. JOURNAL OF VIROLOGY
- Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model
- (2019) Mart Toots et al. Translational Research
- Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses
- (2018) Jeong-Joong Yoon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities
- (2014) Lorenzo Subissi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started